Menu Search
Equities

Astellas Pharma Inc

ALPMY:PNK

Astellas Pharma Inc

Actions
  • Price (USD)10.12
  • Today's Change0.08 / 0.80%
  • Shares traded1.38k
  • 1 Year change-34.03%
  • Beta--
Data delayed at least 15 minutes, as of May 06 2024 15:01 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		4503:TYO since
announced		Transaction
value
Propella Therapeutics IncDeal completed15 Nov 202315 Nov 2023Deal completed-11.25%175.00m
Data delayed at least 20 minutes, as of May 02 2024 07:00 BST.

Institutional shareholders

0.00%Per cent of shares held by top holders
HolderShares% Held
RhumbLine Advisers LPas of 31 Dec 202334.44k0.00%
Johnson Investment Counsel, Inc.as of 29 Feb 202417.60k0.00%
GAMMA Investing LLCas of 31 Mar 20242.40k0.00%
ShariaPortfolio, Inc.as of 04 Apr 20241.84k0.00%
Cassady Schiller Wealth Management LLCas of 31 Dec 2023698.000.00%
PNC Investments LLCas of 31 Dec 2023253.000.00%
Operose Advisors LLCas of 31 Dec 202390.000.00%
First Horizon Advisors, Inc.as of 31 Mar 202437.000.00%
Envestnet Asset Management, Inc.as of 29 Feb 20240.000.00%
Sector Gamma ASas of 31 Dec 20200.000.00%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.